The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program

Drug and Alcohol Dependence

Volumn 89, Issue 2-3, 2007, Pages 306-309

  Raffa, Jesse D ^a   Grebely, Jason ^a   Tossonian, Harout ^a   Wong, Tiffany ^a   Viljoen, Mark ^b   Khara, Milan ^b   Mead, Annabel ^b   McLean, Mark ^b   Duncan, Fiona ^b   Petkau, A John ^a   DeVlaming, Stanley ^b   Conway, Brian ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Pender Community Health Centre   (Canada)

Author keywords

Adherence; Directly observed therapy; Illicit drug use; Methadone

Indexed keywords

AMPHETAMINE; BENZODIAZEPINE; COCAINE; ILLICIT DRUG; METHADONE; OPIATE;

ADULT; ARTICLE; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PARAMETERS OF MEASUREMENT AND ANALYSIS; PHARMACIST; PRIORITY JOURNAL; SOCIAL WELFARE; TREATMENT OUTCOME; URINALYSIS;

AMPHETAMINE-RELATED DISORDERS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZODIAZEPINES; COCAINE-RELATED DISORDERS; COMBINED MODALITY THERAPY; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; METHADONE; NARCOTICS; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STREET DRUGS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS;

EID: 34249058387     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2007.02.007     Document Type: Article

References (21)

1. Altice F.L., Mezger J.A., Hodges J., Bruce R.D., Marinovich A., Walton M., Springer S.A., and Friedland G.H. Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication. Clin. Infect. Dis. 38 Suppl. 5 (2004) S376-S387
2. Bangsberg D.R., Hecht F.M., Charlebois E.D., Zolopa A.R., Holodniy M., Sheiner L., Bamberger J.D., Chesney M.A., and Moss A. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS (London, England) 14 (2000) 357-366
3. Bickel W.K., Stitzer M.L., Bigelow G.E., Liebson I.A., Jasinski D.R., and Johnson R.E. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin. Pharmacol. Therapeutics 43 (1988) 72-78
4. Conway B., Grebely J., Tossonian H., Lefebvre D., and de Vlaming S. A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective. Clin. Infect. Dis. 41 Suppl. 1 (2005) S73-S78
5. Conway B., Prasad J., Reynolds R., Farley J., Jones M., Jutha S., Smith N., Mead A., and DeVlaming S. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin. Infect. Dis. 38 Suppl. 5 (2004) S402-S408
6. Diggle P.J., Heagerty P., Liang K.-Y., and Zeger S.L. Analysis of Longitudinal Data (2002), Oxford University Press, Oxford
7. Gerra G., Borella F., Zaimovic A., Moi G., Bussandri M., Bubici C., and Bertacca S. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend. 75 (2004) 37-45
8. Grebely J., Meagher C., Duncan F., Viljoen M., Khara M., Raffa J., Genoway K., DeVlaming S., Fraser C., and Conway B. Directly Observed Therapy (DOT) for the treatment of Hepatitis C Virus (HCV) Infection in Injection Drug Users (IDUS)-an interim analysis. Hepatology (Baltimore, MD) 42 (2005) S686A
9. Kosten T.R., Schottenfeld R., Ziedonis D., and Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J. Nervous Mental Dis. 181 (1993) 358-364
10. Ling W., Wesson D.R., Charuvastra C., and Klett C.J. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch. Gen. Psychiatry 53 (1996) 401-407
11. Low-Beer S., Yip B., O'Shaughnessy M.V., Hogg R.S., and Montaner J.S. Adherence to triple therapy and viral load response. J. Acquir. Immune Defic. Syndr. (1999) 23 (2000) 360-361
12. Lucas G.M., Weidle P.J., Hader S., and Moore R.D. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study. Clin. Infect. Dis. 38 Suppl. 5 (2004) S409-S413
13. Magura S., Nwakeze P.C., and Demsky S.Y. Pre- and in-treatment predictors of retention in methadone treatment using survival analysis. Addiction (Abingdon, England) 93 (1998) 51-60
14. Mauss S., Berger F., Goelz J., Jacob B., and Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology (Baltimore, MD) 40 (2004) 120-124
15. McHutchison J.G., Manns M., Patel K., Poynard T., Lindsay K.L., Trepo C., Dienstag J., Lee W.M., Mak C., Garaud J.J., and Albrecht J.K. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123 (2002) 1061-1069
16. Paterson D.L., Swindells S., Mohr J., Brester M., Vergis E.N., Squier C., Wagener M.M., and Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133 (2000) 21-30
17. Rowan-Szal G.A., Chatham L.R., and Simpson D.D. Importance of identifying cocaine and alcohol dependent methadone clients. Am. J. Addict. 9 (2000) 38-50
18. Seifert J., Metzner C., Paetzold W., Borsutzky M., Ohlmeier M., Passie T., Hauser U., Becker H., Wiese B., Emrich H., and Schneider U. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone. Addict. Biol. 10 (2005) 157-164
19. Seifert J., Metzner C., Paetzold W., Borsutzky M., Passie T., Rollnik J., Wiese B., Emrich H.M., and Schneider U. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone. Pharmacopsychiatry 35 (2002) 159-164
20. Sofuoglu M., Gonzalez G., Poling J., and Kosten T.R. Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence. Am. J. Drug Alcohol Abuse 29 (2003) 713-727
21. Sylvestre D.L. Treating hepatitis C virus infection in active substance users. Clin. Infect. Dis. 40 Suppl. 5 (2005) S321-S324